Aetna modified CPB 0866 covering rheumatic disease testing, effective January 5, 2026. Here's what billing teams need to know.
Aetna, a CVS Health company, updated its rheumatic diseases selected tests coverage policy under CPB 0866 in the Aetna rheumatoid arthritis and autoimmune testing framework. The most significant addition is the UBA1 mutation test (CPT 0500U) for VEXAS syndrome, now covered under specific criteria. At the same time, Aetna expanded its experimental designation list — adding several new SLE and RA biomarker tests with non-covered codes including 0446U, 0447U, 0521U, and 0522U. If your rheumatology or lab billing team orders or processes these tests, this update changes what gets paid.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Rheumatic Diseases: Selected Tests |
| Policy Code | CPB 0866 |
| Change Type | Modified |
| Effective Date | January 5, 2026 |
| Impact Level | High |
| Specialties Affected | Rheumatology, Clinical Laboratory, Internal Medicine, Hematology |
| Key Action | Add CPT 0500U to charge capture for VEXAS testing; block CPT 0446U, 0447U, 0521U, 0522U from claims without medical necessity review |
Aetna Rheumatic Disease Testing Coverage Criteria and Medical Necessity Requirements 2026
The updated CPB 0866 Aetna coverage policy covers five categories of rheumatic disease testing when specific medical necessity criteria are met. Each one has a defined clinical context. Billing outside that context will get you a claim denial.
HLA-B27 Testing — CPT 81374 and 86812 are covered for diagnosing ankylosing spondylitis and Reiter's syndrome (reactive arthritis). Those are the only covered indications. Don't bill these for general arthritis workups or undifferentiated joint pain.
Anti-CCP Antibodies — CPT 86200 is covered for diagnosis of rheumatoid arthritis. The policy is explicit: this is for RA diagnosis only. Anti-CCP testing billed for any other indication is experimental under this policy.
Myositis Antibody Panel — CPT 83516 is covered for diagnosing inflammatory myopathy. Again, indication-specific. Billing this for RA or other connective tissue disease workups doesn't meet medical necessity under CPB 0866.
Anti-dsDNA Antibodies — CPT 0039U is covered for evaluation and management of systemic lupus erythematosus (SLE). This covers both initial diagnosis and ongoing disease monitoring — a broader scope than some other tests on this list.
UBA1 Mutation Test (VEXAS Syndrome) — This is the new addition in the January 2026 update. CPT 0500U is now covered, but only for adults 18 years or older who present with clinical features of VEXAS syndrome. Those features include recurrent fevers, systemic inflammation involving skin, lungs, cartilage, and/or vasculature, macrocytic anemia, elevated ESR and ferritin, and progressive hematologic abnormalities including cytopenia and vacuolization of myeloid and erythroid precursor cells on bone marrow exam.
That's a long list of criteria. Every item needs to be documented in the medical record before you bill CPT 0500U. If you're not sure whether a patient's chart supports all of these criteria, ask the ordering physician to confirm documentation before claim submission. Talk to your compliance officer if your lab processes these tests in high volume and you haven't built a documentation checklist yet.
The policy does not explicitly list prior authorization requirements for these tests, but prior auth requirements vary by plan. Check the specific Aetna plan before submitting.
Aetna Rheumatic Disease Testing Exclusions and Non-Covered Indications
This is where the update adds real exposure for billing teams. Aetna expanded the experimental, investigational, or unproven list significantly. If you bill any of these, expect denials — and potentially recoupment if prior claims slipped through.
The non-covered list now includes several AI-based SLE tests. The aiSLE DX Disease Activity Index and aiSLE DX Flare Risk Index are both experimental. The Avise CTD assay, Avise SLE, Avise SLE+, and Avise SLE Monitor tests are also excluded — even for ANA-positive patients referred to a rheumatologist for SLE differential diagnosis.
On the RA side, CPT 81490 (Vectra DA, the 12-biomarker autoimmune panel) remains non-covered. PrismRA (CPT 0456U) is experimental. The Seronegative Rheumatoid Arthritis Panel and measurements of anti-CarP antibodies, PAD4, and peripheral T-cells (CPT 86359) are also excluded as RA biomarkers.
For SLE specifically, CPT 0062U (Avise SLE, 80-biomarker IgG and IgM analysis), 0312U, 0446U (10 cytokine mediator analysis), and 0447U (11 cytokine mediator analysis) are all non-covered. CPT 0427U (monocyte distribution width) is also on the exclusion list.
The Early Sjögren's Syndrome Profile and Tissue Specific Markers for Early Diagnosis of Sjögren's Disease (CPT 0522U) are experimental. So is the SLE-key Rule Out Test and measurements of IGF-1 (CPT 84305) for RA management.
The real issue here is that several of these tests — particularly the Avise series and Vectra DA — are actively marketed to rheumatologists and ordered frequently. Labs and physician practices billing for these tests need to audit their Aetna claims now.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Ankylosing spondylitis / Reiter's syndrome diagnosis | Covered | 81374, 86812 | HLA-B27 testing only; diagnosis-specific |
| Rheumatoid arthritis diagnosis | Covered | 86200 | Anti-CCP only; diagnosis use, not monitoring |
| Inflammatory myopathy diagnosis | Covered | 83516 | Myositis antibody panel; not covered for other indications |
| SLE evaluation and management | Covered | 0039U | Anti-dsDNA; covers diagnosis and ongoing management |
| VEXAS syndrome detection (age ≥18) | Covered | 0500U | New 2026 addition; strict clinical criteria required |
| SLE disease activity monitoring (aiSLE DX) | Experimental | — | aiSLE DX Disease Activity Index and Flare Risk Index |
| SLE differential diagnosis (Avise CTD, SLE, SLE+) | Experimental | 0062U, 0312U | Excluded even for ANA-positive patients |
| SLE cytokine biomarker analysis | Experimental | 0446U, 0447U | 10- and 11-cytokine panels |
| SLE rule-out testing (SLE-key) | Experimental | — | No specific CPT listed |
| SLE monitoring (Avise SLE Monitor) | Experimental | — | Not covered for disease activity follow-up |
| RA biomarker panel (Vectra DA) | Experimental | 81490 | All indications excluded |
| RA gene expression (PrismRA) | Experimental | 0456U | NGS-based; not covered |
| RA seronegative panel (KSL/Beutner) | Experimental | 0521U | Early diagnosis use excluded |
| RA anti-CarP, PAD4, peripheral T-cells | Experimental | 86359 | T-cell count code flagged; no specific anti-CarP code listed |
| RA IGF-1 measurement | Experimental | 84305 | Management use excluded |
| RA methotrexate monitoring (Avise MTX) | Experimental | — | No specific CPT listed |
| Sjögren's syndrome (Early Profile) | Experimental | — | No specific CPT listed |
| Sjögren's syndrome (Tissue Specific Markers) | Experimental | 0522U | KSL Diagnostics test |
| Anti-CCP for non-RA indications | Experimental | 86200 | Covered code; non-RA use not covered |
| Monocyte distribution width | Experimental | 0427U | Add-on code; not covered |
| Osteoarthritis/RA 14-3-3 isoforms | Experimental | 83520 | Quantitative immunoassay for this indication |
Aetna Rheumatic Disease Testing Billing Guidelines and Action Items 2026
These are direct steps your billing team should take now. The effective date is January 5, 2026 — which means this policy is already active.
| # | Action Item |
|---|---|
| 1 | Add CPT 0500U to your charge capture for VEXAS testing. This is a new covered service. If your practice or lab orders UBA1 mutation tests, you can now bill 0500U for Aetna members who meet criteria. Build a documentation checklist covering the required clinical features before you submit the first claim. |
| 2 | Audit your Aetna claims for CPT 81490, 0456U, 0062U, 0312U, 0446U, and 0447U. These are all non-covered under CPB 0866. If any of these have been submitted to Aetna and paid, assess your exposure. Aetna can recoup those payments. Talk to your compliance officer before you decide how to handle prior claims. |
| 3 | Block CPT 0521U and 0522U at the payer-level in your billing system. The Seronegative RA Panel (0521U) and Tissue Specific Markers for Sjögren's (0522U) are both experimental. Flag these codes to require a coverage review before any Aetna claim goes out the door. |
| 4 | Confirm documentation for anti-CCP claims (CPT 86200). The covered use is RA diagnosis only. If 86200 is being billed alongside non-RA diagnoses, that's a medical necessity problem. Review your ICD-10 pairing rules for this code. |
| 5 | Check HLA-B27 billing (CPT 81374, 86812) for indication drift. These codes are covered only for ankylosing spondylitis and Reiter's syndrome diagnosis. Pull a 90-day claim sample and confirm your ICD-10 codes are mapping to the right diagnoses — not general arthralgia or undifferentiated arthritis codes. |
| 6 | Verify SLE monitoring reimbursement pathways. Avise SLE Monitor, aiSLE DX, and SLE-key are all experimental. If ordering physicians in your network have been using these tools to manage SLE patients, those claims won't clear Aetna. Talk to your rheumatology department about alternative covered testing strategies — specifically anti-dsDNA (CPT 0039U), which Aetna does cover for SLE management. |
| 7 | Review your Avise test ordering patterns. The entire Avise suite — CTD, SLE, SLE+, SLE Monitor, and MTX — is non-covered under this coverage policy. These are popular tests in rheumatology. Your rheumatologists may not know Aetna doesn't pay for them. A brief provider education note goes a long way toward reducing unnecessary claim denial volume. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Rheumatic Disease Testing Under CPB 0866
Covered CPT Codes (When Medical Necessity Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| 0039U | CPT | DNA antibody, double stranded, high avidity (anti-dsDNA) |
| 0500U | CPT | Autoinflammatory disease (VEXAS syndrome), DNA, UBA1 gene mutations, targeted variant analysis |
| 81374 | CPT | HLA Class I typing, low resolution; one antigen equivalent (e.g., B*27) |
| 83516 | CPT | Immunoassay for analyte other than infectious agent antibody or antigen; qualitative |
| 86200 | CPT | Cyclic citrullinated peptide (CCP), antibody |
| 86812 | CPT | HLA typing; A, B, or C (e.g., A10, B7, B27), single antigen |
Not Covered / Experimental CPT Codes
| Code | Type | Description | Reason |
|---|---|---|---|
| 0062U | CPT | Autoimmune (SLE), IgG and IgM analysis of 80 biomarkers, utilizing serum | Experimental — Avise SLE / Avise CTD |
| 0312U | CPT | Autoimmune diseases (e.g., SLE), analysis of 8 IgG autoantibodies and 2 additional markers | Experimental |
| 0427U | CPT | Monocyte distribution width, whole blood (add-on code) | Experimental |
| 0446U | CPT | Autoimmune diseases (SLE), analysis of 10 cytokine soluble mediator biomarkers | Experimental |
| 0447U | CPT | Autoimmune diseases (SLE), analysis of 11 cytokine soluble mediator biomarkers | Experimental |
| 0456U | CPT | Autoimmune (rheumatoid arthritis), NGS, gene expression testing of 19 genes — PrismRA | Experimental |
| 0521U | CPT | Rheumatoid factor IgA and IgM, CCP antibodies, and scavenger receptor markers — Seronegative RA Panel | Experimental |
| 0522U | CPT | Carbonic anhydrase VI, parotid-specific/secretory protein and salivary protein 1 (SP1), IgG, IgM — Sjögren's Tissue Specific Markers | Experimental |
| 81490 | CPT | Autoimmune (rheumatoid arthritis), analysis of 12 biomarkers using immunoassays — Vectra DA | Experimental |
| 83520 | CPT | Immunoassay for analyte other than infectious agent antibody or antigen; quantitative — 14-3-3 isoforms | Experimental |
| 84305 | CPT | Somatomedin (IGF-1) — for RA management | Experimental |
| 86359 | CPT | T cells; total count — anti-CarP/PAD4 biomarker context | Experimental for RA biomarker use |
Key ICD-10-CM Diagnosis Codes
The full ICD-10 list in CPB 0866 runs 473 codes. Below are the core categories. Check the full policy at app.payerpolicy.org/p/aetna/0866. for the complete list.
| Code Range | Description |
|---|---|
| D46.0–D46.9 | Myelodysplastic syndromes (anemia — relevant to VEXAS criteria) |
| D50.0–D53.9 | Nutritional and other anemias |
| D55.0–D55.9 | Anemias due to enzyme disorders |
| D58.0–D58.9 | Other hereditary hemolytic anemias |
| D59.0–D59.9 | Acquired hemolytic anemias |
| D61.1–D61.9 | Aplastic and other anemias; bone marrow failure syndromes |
| D62 | Acute posthemorrhagic anemia |
| D64.0–D64.9 | Other anemias |
| D65 | Disseminated intravascular coagulation |
The broad anemia code range reflects the hematologic criteria for VEXAS syndrome coverage under CPT 0500U. Document the specific anemia type and bone marrow findings in the chart before billing.
Get the Full Picture for CPT 81374
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.